Fenbendazole's Multi-Targeted Anticancer Activities
Including microtubule disruption, metabolic starvation, p53 activation, and selective induction of oxidative stress.
Fenbendazole (FBZ) is a benzimidazole anthelmintic agent primarily used to treat animal parasitic infections. Preclinical research, however, has highlighted its promising, multi-targeted anticancer activities, which include microtubule disruption, metabolic starvation, p53 activation, and selective induction of oxidative stress.
1. Microtubule Destabilization and Mitotic Arrest
Similar to conventional microtubule-targeting chemotherapies like vincristine and vinblastine, fenbendazole acts as a microtubule destabilizing agent.
It binds directly to tubulin, causing tubulin destabilization and hindering microtubule polymerization.
This microtubule depolymerizing activity interrupts critical cellular processes, such as mitosis and cell structure maintenance, and induces cell cycle arrest in the G2/M phase.
2. Inhibition of Glycolysis and Glucose Uptake (Metabolic Starvation)
Unlike healthy tissue, cancer cells rely heavily on aerobic glycolysis to produce energy and structural building blocks (the Warburg phenotype).
Fenbendazole exploits this dependency by inhibiting glucose uptake and down-regulating glycolysis, effectively starving the cancer cells.
It promotes the mitochondrial translocation of p53, activating the p53-p21 pathway, which down-regulates GLUT1 glucose transporter expression and prevents glucose entry.
Additionally, it is believed to impede hexokinase II (HKII), the first rate-limiting enzyme in the glycolytic pathway.
By blocking glucose metabolism, it reduces intracellular lactate levels, lowering the acidification of the tumor microenvironment and helping reverse drug resistance.
3. Induction of Selective Oxidative Stress
Fenbendazole triggers intracellular oxidative stress (reactive oxygen species accumulation) in cancer cells.
This oxidative stress activates the MEK3/6-p38MAPK signaling pathway, which inhibits cell proliferation and enhances programmed cell death.
4. Activation of p53 and Programmed Cell Death
Fenbendazole is a potent inducer of apoptosis (programmed cell death).
In wild-type (p53-functional) cancer cells, it increases p53 expression and activity by down-regulating its negative regulators, Mdm2 and MdmX.
Cell death is initiated via mitochondrial injury and the caspase 3-PARP signaling pathway.
Crucially, in drug-resistant cells (such as 5-FU-resistant colorectal cancer), it can trigger p53-independent apoptosis and ferroptosis-augmented apoptosis, showing its potential against therapy-resistant tumors.
5. Proteasomal Impairment and Anti-metastatic Effects
Research indicates fenbendazole can impair proteasomal function, leading to potent cytotoxic effects in tumor cells.
It also down-regulates the expression of matrix metalloproteinases (MMP2 and MMP9), which are critical for cell migration, thereby inhibiting cancer cell invasion and metastasis.
Selectivity and Solubility Challenges
Across multiple models, fenbendazole demonstrates selective cytotoxicity, preferentially killing cancer cells while remaining minimally toxic or non-toxic to normal cells. For example, in leukemia models, it showed a 14.5-fold selectivity in killing cancer cells over healthy human bone marrow stem cells.
However, a major hurdle to repurposing fenbendazole for systemic human cancer therapy is its poor water solubility and low oral bioavailability.
To overcome this barrier, research has explored various formulation vehicles, including complexing fenbendazole with methyl-β-cyclodextrin, preparing salicylic acid cocrystals, or encapsulating it in polymeric Soluplus micelles to increase systemic absorption and drug release.
Patients who already have pre-existing liver vulnerabilities—such as compromised liver function, liver cirrhosis, or liver cancer—should use fenbendazole with extreme caution.